Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations
暂无分享,去创建一个
C. Glass | R. Shenkar | I. Awad | Ying Cao | J. Lawler | R. Girard | H. Zeineddine | Thomas Moore | M. Ginsberg | F. Lagarrigue | Gregory Fonseca | M. Lopez-Ramirez | Angela Pham | Bart-Jan de Kreuk
[1] H. Jo,et al. KLF2 and KLF4 control endothelial identity and vascular integrity. , 2017, JCI insight.
[2] Courtney P Orsbon,et al. Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease , 2016, Journal of Neuroscience Methods.
[3] C. Glass,et al. Tissue damage drives co-localization of NF-κB, Smad3, and Nrf2 to direct Rev-erb sensitive wound repair in mouse macrophages , 2016, eLife.
[4] Zinan Zhou,et al. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signaling , 2016, Nature.
[5] M. Corada,et al. KLF4 is a key determinant in the development and progression of cerebral cavernous malformations , 2015, EMBO molecular medicine.
[6] R. Keep,et al. PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk , 2015, Acta Neuropathologica.
[7] R. Shenkar,et al. Vascular Permeability in Cerebral Cavernous Malformations , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] L. Morrison,et al. Increased Number of White Matter Lesions in Patients with Familial Cerebral Cavernous Malformations , 2015, American Journal of Neuroradiology.
[9] R. Drapkin,et al. Combined therapy with thrombospondin‐1 type I repeats (3TSR) and chemotherapy induces regression and significandy improves survival in a preclinical model of advanced stage epithelial ovarian cancer , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[10] Dean Y. Li,et al. The cerebral cavernous malformation pathway controls cardiac development via regulation of endocardial MEKK3 signaling and KLF expression. , 2015, Developmental cell.
[11] A. Benz,et al. Regulation of β1 integrin-Klf2-mediated angiogenesis by CCM proteins. , 2015, Developmental cell.
[12] M. Corada,et al. KLF 4 is a key determinant in the development and progression of cerebral cavernous malformations , 2015 .
[13] I. Sarelius,et al. KRIT1 Protein Depletion Modifies Endothelial Cell Behavior via Increased Vascular Endothelial Growth Factor (VEGF) Signaling* , 2014, The Journal of Biological Chemistry.
[14] D. Corcoran,et al. Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. , 2014, Human molecular genetics.
[15] B. Sharrack,et al. MicroRNA‐155 negatively affects blood–brain barrier function during neuroinflammation , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] L. Ferrarini,et al. EndMT contributes to the onset and progression of cerebral cavernous malformations , 2013, Nature.
[17] M. Gunel,et al. Ultrastructural analysis of vascular features in cerebral cavernous malformations , 2013, Clinical Neurology and Neurosurgery.
[18] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[19] A. Schmaier,et al. Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. , 2012, The Journal of clinical investigation.
[20] Jeremy Seto,et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. , 2012, The Journal of clinical investigation.
[21] J. Lawler,et al. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. , 2012, Cold Spring Harbor perspectives in medicine.
[22] R. Shenkar,et al. Fasudil Decreases Lesion Burden in a Murine Model of Cerebral Cavernous Malformation Disease , 2012, Stroke.
[23] Peter J. Bickel,et al. Measuring reproducibility of high-throughput experiments , 2011, 1110.4705.
[24] E. Dejana,et al. Developmental timing of CCM2 loss influences cerebral cavernous malformations in mice , 2011, The Journal of experimental medicine.
[25] J. Bockaert,et al. Epileptiform Activity Induces Vascular Remodeling and Zonula Occludens 1 Downregulation in Organotypic Hippocampal Cultures: Role of VEGF Signaling Pathways , 2011, The Journal of Neuroscience.
[26] K. Frei,et al. Impairment of Tight Junctions and Glucose Transport in Endothelial Cells of Human Cerebral Cavernous Malformations , 2011, Journal of neuropathology and experimental neurology.
[27] D. Mosher,et al. Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation. , 2011, American journal of physiology. Lung cellular and molecular physiology.
[28] M. Avolio,et al. Mutation Analysis of CCM1, CCM2 and CCM3 Genes in a Cohort of Italian Patients with Cerebral Cavernous Malformation , 2011, Brain pathology.
[29] R. Kucherlapati,et al. A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. , 2011, Human molecular genetics.
[30] R. Adams,et al. Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice , 2010, Nature Protocols.
[31] Ulrich Sure,et al. Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling , 2010, Proceedings of the National Academy of Sciences.
[32] T. Czymai,et al. Erk5 Activation Elicits a Vasoprotective Endothelial Phenotype via Induction of Krüppel-like Factor 4 (KLF4)* , 2010, The Journal of Biological Chemistry.
[33] C. Glass,et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.
[34] R. Shenkar,et al. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity , 2010, The Journal of experimental medicine.
[35] F. Orsenigo,et al. CCM1 regulates vascular-lumen organization by inducing endothelial polarity , 2010, Journal of Cell Science.
[36] M. Ginsberg,et al. Rap1 and its effector KRIT1/CCM1 regulate β-catenin signaling , 2010, Disease Models & Mechanisms.
[37] D. Roberts,et al. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies , 2009, Nature Reviews Cancer.
[38] M. Weichenthal,et al. The angiogenesis inhibitor thrombospondin-1 inhibits acute cutaneous hypersensitivity reactions. , 2009, The Journal of investigative dermatology.
[39] Christopher A. Jones,et al. The Cerebral Cavernous Malformation signaling pathway promotes vascular integrity via Rho GTPases , 2009, Nature Medicine.
[40] P. Chambon,et al. Efficient, inducible Cre‐recombinase activation in vascular endothelium , 2008, Genesis.
[41] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[42] M. Ginsberg,et al. KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell–cell junctions , 2007, The Journal of cell biology.
[43] Issam A Awad,et al. CONCEPTS AND HYPOTHESES: INFLAMMATORY HYPOTHESIS IN THE PATHOGENESIS OF CEREBRAL CAVERNOUS MALFORMATIONS , 2007, Neurosurgery.
[44] J. Lawler,et al. Thrombospondin-based antiangiogenic therapy. , 2007, Microvascular research.
[45] E. Edelman,et al. Kruppel-like Factor 4 Regulates Endothelial Inflammation* , 2007, Journal of Biological Chemistry.
[46] H. Groen,et al. A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] Yuzhi Zhang,et al. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. , 2005, The Journal of clinical investigation.
[48] H. Groen,et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] G. Garcı́a-Cardeña,et al. Kruppel-Like Factor 2 (KLF2) Regulates Endothelial Thrombotic Function , 2005, Circulation research.
[50] D. Ingber,et al. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β1 integrins , 2005, The Journal of cell biology.
[51] Dean Y. Li,et al. Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations , 2004, Development.
[52] K. Chu,et al. Cerebral cavernous malformations with dynamic and progressive course: correlation study with vascular endothelial growth factor. , 2003, Archives of neurology.
[53] J. Lawler,et al. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. , 2001, Cancer research.
[54] R. Hynes,et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[55] O. Volpert,et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.
[56] R. Hynes,et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. , 1998, The Journal of clinical investigation.